22nd Century Group Stock Price Rises 2.5%

Analysts debate whether it's time to buy the biotech company's shares.

Published on Feb. 8, 2026

Got story updates? Submit your updates here. ›

22nd Century Group, Inc. (NASDAQ:XXII), a plant biotechnology company, saw its share price rise 2.5% during mid-day trading on Friday. The company's stock reached as high as $5.97 before closing at $5.81, with trading volume increasing 193% from the average daily volume.

Why it matters

22nd Century Group is known for its work in developing reduced-nicotine tobacco products and hemp cultivation, which are areas of growing public health and consumer interest. The stock's price movement and trading volume suggest potential investor interest, though analysts remain divided on the company's outlook.

The details

The increase in 22nd Century Group's stock price and trading volume came amid mixed analyst sentiment. Wall Street Zen upgraded the stock from a 'sell' rating to 'hold', while Weiss Ratings maintained a 'sell (e+)' rating. Overall, the consensus rating on the stock is 'Sell' according to data from MarketBeat.com.

  • 22nd Century Group's stock price rose 2.5% during mid-day trading on Friday, February 8, 2026.
  • In the third quarter, an institutional investor, Anson Funds Management LP, increased its stake in 22nd Century Group by 197.3%, owning approximately 1.41% of the company's shares.

The players

22nd Century Group, Inc.

A plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species, with a focus on developing reduced-nicotine tobacco products and hemp cultivation.

Anson Funds Management LP

An institutional investor that recently increased its stake in 22nd Century Group by 197.3%, now owning approximately 1.41% of the company's shares.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The mixed analyst sentiment and increased institutional investment in 22nd Century Group suggest the company's reduced-nicotine tobacco and hemp-related products may be generating investor interest, though the overall outlook remains uncertain.